Source: Simply Wall St.
Elanco Animal Health Incorporated has witnessed a significant 72% increase in its share price in the last quarter, providing a positive sign for shareholders. However, over the past five years, the stock has experienced a decline of 48%, underperforming index funds. Elanco Animal Health is currently not profitable, and its revenue growth has been the primary focus for assessing its performance. The company has achieved a respectable 11% annual revenue growth over the last five years.
Still, this growth has not translated into a rise in share price, which has declined by 8% annually during the same period. Shareholders who believed in stronger growth and profits have been disappointed. While insiders have made significant purchases recently, future earnings will play a vital role in determining the company’s success. The stock has returned 8% in the past year, trailing the overall market. Over the long term, the stock’s performance should be considered alongside other factors and potential risks.
Read the full story HERE: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/even-after-rising-40-this-past-week-elanco-animal-health-nys